Closed Fund Six of Brandon Capital surpasses A$439 million in capital.
Brandon Capital's Brandon BioCatalyst Fund Six (BB6) Closes at A$439 Million
Brandon Capital, a leading life sciences venture capital firm in Australasia, has successfully closed its sixth fund, the Brandon BioCatalyst Fund Six (BB6), with a total of A$439 million. This marks the largest fund raised by Brandon Capital to date.
The BB6 fund focuses on investing in emerging biomedical technologies that translate scientific discoveries into high-growth companies dedicated to improving human health. Notable investors in the fund include the Western Australia Government, Australia’s National Reconstruction Fund Corporation (NRFC), Hesta, Host Plus, CSL, and QIC.
Recent notable successes under the BB6 fund include companies that have achieved significant regulatory approvals, such as therapies from George Medicines and EBR Systems approved by the FDA, and Q-Sera's approval in Japan. Key investments from the fund include AdvanCell (radiopharmaceuticals), PolyActiva (glaucoma implant), Myricx Bio (antibody-drug conjugates, ADC), and CatalYm (oncology).
The fund supports over 30 companies and more than 270 skilled jobs in Australia, contributing significantly to the biomedical manufacturing sector while fostering global collaboration and bolstering Australia's research capabilities. The NRFC’s $150 million commitment specifically supports early and late-stage Australian medical science companies through clinical and technical development, regulatory approvals, and job creation, enhancing Australia's position as a global hub for advanced medical science and health technology.
NRFC CEO David Gall emphasized the importance of investing in medical science today to ensure its existence in Australia in ten years. He stated that the NRFC recognizes the long development timelines in medical science and aims to make early and considered investments.
Brandon Capital remains committed to advancing breakthrough biomedical innovations through scientific rigor and disciplined capital allocation. The firm's investments contribute significantly to the manufacturing sector in Australia while fostering global collaboration and enhancing Australia's research capabilities.
The NRFC's investment in BB6 is a strategic move to attract talent and capital for local commercialization capabilities in medical science. This partnership is expected to drive further growth and innovation in the biomedical sector in Australia.
Venture capital firm Brandon Capital, having closed its sixth fund, the Brandon BioCatalyst Fund Six (BB6), with A$439 million, will now invest in growth companies with a focus on biomedical technologies that translate science into solutions for improving human health. This investment from the NRFC, alongside other notable investors, supports more than 30 companies, bolstering Australia's biomedical manufacturing sector and fostering global collaboration.
